Table 1 Summary of clinicopathologic variables in salivary gland cancer patients.

From: LMW cyclin E and its novel catalytic partner CDK5 are therapeutic targets and prognostic biomarkers in salivary gland cancers

Variable

Aci (N = 80)

AdCC (N = 215)

MEC (N = 82)

SDC (N = 105)

No. (%)

p Value

No. (%)

p Value

No. (%)

p Value

No. (%)

p Value

Age, years

Median

60

0.1123

62

0.9492

63.5

0.3073

65

0.01517

Mean (range)

60 (23–90)

 

63 (27–96)

 

61 (22–97)

 

66 (37–96)

 

Sex

Female

47 (60.26)

0.1152

113 (52.56)

0.732

51 (62.2)

0.0439

36 (34.29)

0.0001

Male

31 (39.74)

 

102 (47.44)

 

31 (37.8)

 

69 (65.71)

 

Race

White

63 (78.75)

0.8144*

160 (74.42)

0.08771

60 (73.2)

0.2126

95 (90.48)

0.0029

Black

3 (3.75)

 

16 (7.44)

 

3 (3.7)

 

4 (3.81)

 

Hispanic

11 (13.75)

 

29 (13.49)

 

15 (18.3)

 

5 (4.76)

 

Others

3 (3.75)

 

10 (4.65)

 

4 (4.9)

 

2 (0.95)

 

Tumor size (CM)

Median

2.3

0.03424

3

0.4788

2

0.05264

3

0.01175

Mean (range)

2.6 (0.8–6.5)

 

3.1 (0.5–15)

 

2.7 (1–6)

 

3.4 (0.7–10)

 

Tumor grade

Low

4 (15.4)

0.0142**

13 (14.13)

<0.0001

15 (18.7)

0.0003

3 (4.11)

<0.0001

Intermediate

2 (7.7)

 

50 (54.35)

 

40 (50.0)

 

8 (10.96)

 

High

20 (76.9)

 

29 (31.52)

 

25 (31.3)

 

62 (84.93)

 

Perineural invasion

No

54 (77.14)

<0.0001

56 (26.42)

<0.0001

65 (80.3)

<0.0001

39 (41.94)

0.334

Yes

16 (22.86)

 

156 (73.58)

 

16 (19.7)

 

54 (58.06)

 

Lymphovascular invasion

No

62 (88.57)

0.07545

178 (84.36)

0.0431

68 (83.9)

0.414

57 (60.64)

<0.0001

Yes

8 (11.43)

 

33 (15.64)

 

13 (16.1)

 

37 (39.36)

 

Margin

Negative

51 (75.0)

0.05616

102 (49.28)

<0.0001

61 (74.4)

0.04181

76 (79.17)

0.0007

Positive

17 (25.0)

 

105 (50.72)

 

21 (25.6)

 

20 (20.83)

 

LMW-E (H-score)

0

57 (75.0)

0.01799

113 (63.13)

0.8748

60 (75.0)

0.01437

39 (40.62)

<0.0001

1

19 (25.0)

 

66 (36.87)

 

20 (25.0)

 

57 (59.38)

 

CDK5 H-score

0

50 (65.79)

0.03849

95 (52.49)

0.5621

47 (59.5)

0.3783

43 (44.79)

0.0427

1

26 (34.21)

 

86 (47.51)

 

32 (40.5)

 

53 (55.21)

 

Clinical TNM stage

I

15 (23.08)

0.2042

13 (6.7)

0.0003

22 (28.6)

<0.0001

12 (13.33)

0.0021

II

10 (15.38)

 

33 (17.01)

 

21 (27.3)

 

4 (4.44)

 

III

7 (10.77)

 

27 (13.92)

 

6 (7.8)

 

8 (8.89)

 

IV

33 (50.77)

 

121 (62.37)

 

28 (36.3)

 

66 (73.33)

 

Combined LMW-E and CDK5 (H-score)

Both negative

46 (75.41)

0.02247

75 (61.98)

1

43 (53.8)

0.04726

29 (40.28)

<0.0001

Both positive

15 (24.59)

 

46 (38.02)

 

15 (18.7)

 

43 (59.72)

 

Primary tumor sitea

Parotid gland

74 (92.5)

<0.0001

31 (14.4)

<0.0001

27 (32.9)

0.0098

82 (78.1)

<0.0001

Submandibular gland

2 (2.5)

 

21 (9.8)

 

3 (3.7)

 

8 (7.6)

 

Sublingual gland

0 (0)

 

2 (0.9)

 

1 (1.2)

 

0 (0)

 

Maxilla and maxillary sinuses

0 (0)

 

56 (26.1)

 

10 (12.2)

 

4 (3.8)

 

Others

4 (5.0)

 

105 (48.8)

 

41 (50.0)

 

11 (10.5)

 
  1. *p Value after combining “Black” and “Others” categories.
  2. **p Value after combining “Low” and “Intermediate” categories.
  3. aSupplementary Table 2 lists all the sites.
  4. Summary of clinicopathologic variables in patients with Aci (N = 80), AdCC (N = 215), MEC (N = 82), and SDC (N = 105) subtypes of salivary gland primary tumors from patients. For tests of homogeneity of each subtype, one-way ANOVA and chi-squared tests were used to compare distributions of continuous and categorical factors between the subtype group and other subtypes (pooled).
Back to article page